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Introduction {#sec005}
============

Coronavirus disease-- 2019 (COVID-19) is a disease that was detected in December 2019 in Wuhan, China, and led to the risk of mortality of about 2% \[[@pone.0238160.ref001]\]. This disease is caused due to infection with a recently arising zoonotic virus known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) \[[@pone.0238160.ref002]\]. Previously, infection with coronaviruses appeared in 2002 within China in the form of SARS-CoV, and it appeared later also in 2012 within Saudi Arabia that was known as Middle East Respiratory Syndrome (MERS-CoV) \[[@pone.0238160.ref003], [@pone.0238160.ref004]\]. All these coronaviruses are enveloped positive-strand RNA viruses that are isolated from bats that can be transferred from animals to humans, human to human, and animals to animals \[[@pone.0238160.ref005]\]. They share a similarity in the clinical symptoms in addition to specific differences that have been recently observed \[[@pone.0238160.ref005]--[@pone.0238160.ref007]\]. The symptoms of this disease appear with different degrees that start in the first seven days with mild symptoms such as fever, cough, shortness of breath, and fatigue \[[@pone.0238160.ref008]\]. Afterward, critical symptoms may develop in some patients involving dyspnea and pneumonia that require patient's management in intensive care units to avoid the serious respiratory complications that may lead to death \[[@pone.0238160.ref009]\]. However, there are no specific symptoms to diagnose coronavirus infection, and accurate testing depends on the detection of the viral genome using the reverse transcription-polymerase chain reaction (RT-PCR) analysis \[[@pone.0238160.ref010]\].

Unfortunately, COVID-19 is not limited to its country of origin, but it has spread all over the world. Therefore, there is no wonder emerging research has been directed to provide information and clinical data of patients infected with this virus that may help to not only to the early detection in different patient categories, but it will also help in the characterization of the viral complications with other chronic diseases \[[@pone.0238160.ref001], [@pone.0238160.ref002], [@pone.0238160.ref006], [@pone.0238160.ref009]\]. However, there is no sufficient data that characterize the changes in the hematological and immunological parameters in COVID-19 patients. In the current comprehensive meta-analysis study, we aimed to analyze different hematological, inflammatory, and immunological markers in COVID-19 patients at different clinical stages in different countries that may help in the early detection of COVID-19 infection and to discriminate between severity status of the disease to decrease the death risk.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

This current meta-analysis was carried out according to the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement \[[@pone.0238160.ref011]\] ([S1 Table](#pone.0238160.s001){ref-type="supplementary-material"}). Relevant literature was retrieved from Web of Science, PubMed, Scopus, and Science Direct search engines up to April 22, 2020. Our search strategy included the following terms: "Novel coronavirus 2019", "2019 nCoV", "COVID-19", "Wuhan coronavirus," "Wuhan pneumonia," or "SARS-CoV-2". Besides, we manually screened out the relevant potential article in the references selected. The above process was performed independently by three participants.

Study selection {#sec008}
---------------

No time or language restriction was applied. Inclusion criteria were as follows: (1) Types of Studies: retrospective, prospective, observational, descriptive or case control studies reporting laboratory features of COVID-19 patients; (2) Subjects: diagnosed patients with COVID-19 (3) Exposure intervention: COVID-19 patients diagnosed with Real Time-Polymerase Chain Reaction, radiological imaging, or both; with hematological testing included: complete blood picture (white blood cells, neutrophil count, lymphocyte count, monocyte count, eosinophils count, basophils, red blood cells, hemoglobin, hematocrit, and platelet count), coagulation profile (prothrombin time, international normalized ratio, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimer) or immunological parameters including inflammatory markers (ferritin, erythrocyte sedimentation rate, procalcitonin, and C-reactive protein), immunoglobulins (IgA, IgG, and IgM), complement tests (C3 and C4), interleukins (IL-4, IL-6, IL-8, IL-10, IL-2R, and TNF-α), and immune cells (B lymphocytes, T lymphocytes, CD4^+^ T cells, and CD8^+^ T cells); and (4) Outcome indicator: the mean and standard deviation or median and interquartile range for each laboratory test. The following exclusion criteria were considered: (1) Case reports, reviews, editorial materials, conference abstracts, summaries of discussions, (2) Insufficient reported data information; or (3) *In vitro* or *in vivo* studies.

Data abstraction {#sec009}
----------------

Four investigators separately conducted literature screening, data extraction, and literature quality evaluation, and any differences were resolved through another two reviewers. Information extracted from eligible articles in a predesigned form in excel, including the last name of the first author, date and year of publication, journal name, study design, country of the population, sample size, mean age, sex, and quality assessment.

Quality assessment {#sec010}
------------------

A modified version of the Newcastle-Ottawa scale (NOS) was adopted to evaluate the process in terms of queue selection, comparability of queues, and evaluation of results \[[@pone.0238160.ref012], [@pone.0238160.ref013]\]. The quality of the included studies was assessed independently by three reviewers, and disagreements were resolved by the process described above. Higher NOS scores showed a higher literature quality. NOS scores of at least six were considered high-quality literature.

Statistical analysis {#sec011}
--------------------

All data analysis was performed using OpenMeta\[Analyst\] \[[@pone.0238160.ref014]\] and comprehensive meta-analysis software version 3.0 \[[@pone.0238160.ref015]\]. First, a single-arm meta‐analysis for laboratory tests was performed. The standardized mean difference (SMD) and 95%confidence intervals (CI) were used to estimate pooled results from studies. Medians and interquartile range were converted to mean and standard deviation (SD) using the following formulas: \[Mean = (Q1+median+Q3)/3\] and \[SD = IQR/1.35\], whereas, values reported in the articles as mean and 95%CI were estimated using the following formula \[SD = √N \* (Upper limit of CI--Lower limit of CI)/3.92\]. A continuous random-effect model was applied using the DerSimonian-Laird (inverse variance) method \[[@pone.0238160.ref016], [@pone.0238160.ref017]\].

Next, in the presence of individual patient data, single-armed observed values were converted to two-armed data to act as each other's control group based on covariate information. Only studies investigating different outcomes were considered as potential matched pairs, and two-arm meta-analysis was applied to compare between mild *versus* severe COVID-19 infection (based on the results of the chest radiography, clinical examination, and symptoms), ICU admission *versus* general ward admission, and expired *versus* survivors. Meta-analysis for each outcome was processed using a random-effects model since heterogeneity among studies was expected. For pairwise comparison, estimates of SMD served as quantitative measures of the strength of evidence, which were then converted to the odds ratio (OR) with 95%CI for better interpretation by clinical domains.

Decision tree to identify predictors for poor outcomes {#sec012}
------------------------------------------------------

Using laboratory features for clinical prediction, the decision tree algorithm was employed to identify the key risk factors attributed to severe COVID-19 infection, which include a count of studies ≥10. The accuracy of the model was measured by the Area Under the Receiver Operating Characteristic (ROC) Curve (AUC), which depicts the true positive rate versus the false positive rate at various discrimination thresholds. The markers that have the highest AUC were identified, and the sensitivity and specificity of the cut-off threshold level were determined. R Studio was employed using the following packages: *tidyverse*, *magrittr*, *rpart*, *caret*, and *pROC*.

Trial sequential analysis (TSA) {#sec013}
-------------------------------

The statistical trustworthiness of this meta-analysis assessment was conducted using TSA through combining the cumulative sample sizes of all appropriate records with the threshold of statistical impact to diminish the accidental errors and enhance the intensity of expectations \[[@pone.0238160.ref018]\]. Two side trials with "type I error (α)" along with power set at 5% and 80% were employed. In the case of the "Z-curve" traverses the TSA monitoring boundaries, a reasonable degree of impact was accomplished, and no supplementary trials are crucial. Nevertheless, in case of the "Z-curve" failed to achieve the boundary limits, the estimated information size has not accomplished the required threshold to attract appropriate decisions and advance trials are mandatory. TSA platform (version 0.9.5.10 beta) was operated in the experiment.

Assessment of heterogeneity and publication bias {#sec014}
------------------------------------------------

After that, the heterogeneity was evaluated using Cochran's Q statistic and quantified by using I^2^ statistics, which represents an estimation of the total variation across studies beyond chance. Articles were considered to have significant heterogeneity between studies when the *p-value* less than 0.1 or I^2^ greater than 50%. Subgroup analysis was performed based on the study sample size (≤50 patients compared to \>50 patients) and the origin of patients (Wuhan city versus others). Also, sensitivity analyses and meta-regression with the random-effects model using restricted maximum likelihood algorithm were conducted to explore potential sources of heterogeneity.

Finally, publication bias was assessed using a funnel plot and quantified using Begg's and Mazumdar rank correlation with continuity correction and Egger's linear regression tests. Asymmetry of the collected studies' distribution by visual inspection or *P-value* \< 0.1 indicated obvious publication bias \[[@pone.0238160.ref019]\]. The Duval and Tweedie's trim and fill method's assumption were considered to reduce the bias in pooled estimates \[[@pone.0238160.ref020]\].

Results {#sec015}
=======

Literature search {#sec016}
-----------------

A flowchart outlining the systematic review search results is described in [Fig 1A](#pone.0238160.g001){ref-type="fig"}. A total of 4752 records were identified through four major electronic databases till April 22, 2020 including Web of Science (n = 557), PubMed (n = 1688), Scopus (n = 1105) and Science Direct (n = 1402). Upon reviewing the retrieved articles, a total of 1230 records were excluded for duplication, and 3522 unique records were initially identified. Following screening of titles and abstracts, several studies were excluded for being case reports (n = 44), review articles (n = 262), irrelevant publications (n = 1355), or editorial materials (n = 1809). The resulted 424 full-text publications were further assessed for eligibility, during which 372 records were removed for lacking sufficient laboratory data. Ultimately, a total of 52 eligible articles were included for the quantitative synthesis of this meta-analysis study, with 52 records represented single-arm analysis \[[@pone.0238160.ref001], [@pone.0238160.ref009], [@pone.0238160.ref021]--[@pone.0238160.ref070]\], 16 records represented two-arms severity analysis \[[@pone.0238160.ref024], [@pone.0238160.ref026], [@pone.0238160.ref032], [@pone.0238160.ref034], [@pone.0238160.ref037], [@pone.0238160.ref040], [@pone.0238160.ref041], [@pone.0238160.ref045], [@pone.0238160.ref046], [@pone.0238160.ref050], [@pone.0238160.ref051], [@pone.0238160.ref063], [@pone.0238160.ref064], [@pone.0238160.ref066], [@pone.0238160.ref069], [@pone.0238160.ref070]\]; meanwhile, 7 and 4 records were utilized for survival \[[@pone.0238160.ref009], [@pone.0238160.ref030], [@pone.0238160.ref053], [@pone.0238160.ref055], [@pone.0238160.ref061], [@pone.0238160.ref067], [@pone.0238160.ref068]\] and ICU admission \[[@pone.0238160.ref001], [@pone.0238160.ref031], [@pone.0238160.ref036], [@pone.0238160.ref052]\] analyses, respectively.

![Literature search process.\
(A) Workflow for screening and selecting relevant articles. (B) Map showing the location of the studies. Studies conducted in China (red), Taiwan (green), Singapore (blue), and USA (light blue) are shown with the number of studies between brackets. Data source Tableau 2020.1 Desktop Professional Edition (<https://www.tableau.com/>).](pone.0238160.g001){#pone.0238160.g001}

### Characteristics of the included studies {#sec017}

Our review included 52 studies that were published from January 24 through April 22, 2020, including 48 articles from China \[Wuhan (30), Chongqing (4), Zhejiang (4), Shanghai (2), Ningbo (1), Hong Kong (1), Shenzhen (1), Anhui (1), Macau (1), Hainan (1), Jiangsu (1), and Beijing (1)\], two articles from Singapore \[Singapore and Sengkang\], one article from Taiwan \[Taichung\], and one article from USA \[Washington\] ([Fig 1B](#pone.0238160.g001){ref-type="fig"}). The main characteristics of eligible studies are shown in [Table 1](#pone.0238160.t001){ref-type="table"}. A total of 6320 patients with SARS‐CoV‐2 infection were enrolled across the articles. Most records (n = 47) were retrospective case studies, while other study design included two prospective cohort studies, one observational cohort study, one descriptive case series, and one case-control study. Our team stratified 36 different laboratory parameters into seven subclasses, including complete blood picture, coagulation profile, immunological markers, immunoglobulins, complement tests, interleukins, and immune cells, as previously described in the methodology. Regarding quality score assessment, 39 studies achieved a score higher than six out of a maximum of nine (high quality), while the remaining 13 studies earned a score equal or lower than six (low quality), as shown in [Table 1](#pone.0238160.t001){ref-type="table"}.

10.1371/journal.pone.0238160.t001

###### General characteristics of the included studies.
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  First Author   Publication[\*](#t001fn001){ref-type="table-fn"} date (dd-mm)   Continent    Country     Study design                 Sample size   Quality score   Mean age, years   Female %   Outcome     Ref.
  -------------- --------------------------------------------------------------- ------------ ----------- ---------------------------- ------------- --------------- ----------------- ---------- ----------- ----------------------------
  Zhu Z          22-April                                                        Ningbo       China       Retrospective case study     127           9               50.9 (15.3)       64.6%      Severity    \[[@pone.0238160.ref070]\]
  Liu X          20-April                                                        Wuhan        China       Retrospective case study     124           8               56 (12)           57.1%      Severity    \[[@pone.0238160.ref040]\]
  Chen X         18-April                                                        Wuhan        China       Retrospective case study     48            9               64.6 (18.1)       22.9%      Severity    \[[@pone.0238160.ref026]\]
  Chen G         13-April                                                        Wuhan        China       Retrospective case study     21            8               57 (11.1)         19%        Severity    \[[@pone.0238160.ref024]\]
  He R           12-April                                                        Wuhan        China       Retrospective case study     204           9               48.3 (20.7)       61.3%      Severity    \[[@pone.0238160.ref034]\]
  Zhang G        09-April                                                        Wuhan        China       Retrospective case study     221           9               53.5 (20.4)       51.1%      Severity    \[[@pone.0238160.ref063]\]
  Lei S          04-April                                                        Wuhan        China       Retrospective case study     34            9               53.7 (14.8)       58.8%      ICU         \[[@pone.0238160.ref036]\]
  Wang L         30-March                                                        Wuhan        China       Retrospective case study     339           8               69 (7.4)          51%        Mortality   \[[@pone.0238160.ref053]\]
  Guo T          27-March                                                        Wuhan        China       Retrospective case study     187           8               58.5 (14.7)       51.3%      NA          \[[@pone.0238160.ref033]\]
  Zheng C        27-March                                                        Wuhan        China       Retrospective case study     55            7               57.2 (65.3)       43.6%      Severity    \[[@pone.0238160.ref066]\]
  Chen T         26-March                                                        Wuhan        China       Retrospective case study     274           9               58.7 (19.2)       37.6%      Mortality   \[[@pone.0238160.ref009]\]
  Tang X         26-March                                                        Wuhan        China       Retrospective case study     73            6               65.3 (11.1)       38.4%      NA          \[[@pone.0238160.ref049]\]
  Shi S          25-March                                                        Wuhan        China       Retrospective case study     416           9               60 (54.8)         50.7%      NA          \[[@pone.0238160.ref048]\]
  TO K           23-March                                                        Hong Kong    China       Observational cohort study   23            9               57.7 (27.5)       43.5%      Severity    \[[@pone.0238160.ref050]\]
  Zhou Z         24-March                                                        Chongqing    China       Retrospective case study     62            9               47.2 (13.4)       45.2%      Severity    \[[@pone.0238160.ref069]\]
  Chen Z         24-March                                                        Zhejiang     China       Retrospective case study     98            6               43 (17.2)         53.1%      NA          \[[@pone.0238160.ref027]\]
  Wan S          21-March                                                        Chongqing    China       Retrospective case study     135           9               46 (14.1)         46.7%      Severity    \[[@pone.0238160.ref051]\]
  Cheng Y        20-March                                                        Wuhan        China       Prospective cohort study     701           9               61.3 (15.5)       47.6%      NA          \[[@pone.0238160.ref028]\]
  Luo S          20-March                                                        Wuhan        China       Retrospective case study     183           5               53.8 (NA)         44%        NA          \[[@pone.0238160.ref042]\]
  Deng Y         20-March                                                        Wuhan        China       Retrospective case study     225           8               55.4 (11.5)       44.9%      Mortality   \[[@pone.0238160.ref030]\]
  Arentz M       19-March                                                        Washington   USA         Retrospective case study     21            5               68.3 (36.3)       48%        NA          \[[@pone.0238160.ref021]\]
  Chen J         19-March                                                        Shanghai     China       Retrospective case study     249           5               50.3 (20.7)       49.4%      NA          \[[@pone.0238160.ref025]\]
  Cai Q          18-March                                                        Shenzhen     China       Retrospective case study     80            9               47.9 (18.7)       56.2%      NA          \[[@pone.0238160.ref022]\]
  Gao Y          17-March                                                        Anhui        China       Retrospective case study     43            9               43.7 (11.8)       39.5%      Severity    \[[@pone.0238160.ref032]\]
  Qian G         17-March                                                        Zhejiang     China       Retrospective case study     91            5               47.8 (15.2)       59.3%      Severity    \[[@pone.0238160.ref045]\]
  Mo P           16-March                                                        Wuhan        China       Retrospective case study     155           8               54 (17.8)         44.5%      NA          \[[@pone.0238160.ref043]\]
  Wang Z         16-March                                                        Wuhan        China       Retrospective case study     69            7               46.3 (20)         54%        NA          \[[@pone.0238160.ref054]\]
  Lo I           15-March                                                        Macau        China       Retrospective case study     10            8               48.3 (27.4)       70%        Severity    \[[@pone.0238160.ref041]\]
  Cheng Z        14-March                                                        Shanghai     China       Retrospective case study     11            5               50.4 (15.5)       27.3%      NA          \[[@pone.0238160.ref029]\]
  Hsih W         13-March                                                        Taichung     Taiwan      Retrospective case study     2             5               45 (8.9)          50%        NA          \[[@pone.0238160.ref035]\]
  Wu C           13-March                                                        Wuhan        China       Retrospective case study     201           8               51.3 (12.6)       36.3%      Mortality   \[[@pone.0238160.ref055]\]
  Qin C          12-March                                                        Wuhan        China       Retrospective case study     452           9               57.3 (14.8)       48%        Severity    \[[@pone.0238160.ref046]\]
  Zhao D         12-March                                                        Wuhan        China       Case-control study           19            7               43.7 (21.5)       42.1%      NA          \[[@pone.0238160.ref065]\]
  Liu K          11-March                                                        Hainan       China       Retrospective case study     18            7               67.6 (3.3)        33.3%      NA          \[[@pone.0238160.ref038]\]
  Zhou F         09-March                                                        Wuhan        China       Retrospective case study     191           9               56.3 (15.5)       38%        Mortality   \[[@pone.0238160.ref067]\]
  Xiong Y        07-March                                                        Wuhan        China       Retrospective case study     42            5               49.5 (14.1)       40%        NA          \[[@pone.0238160.ref058]\]
  Fan B          04-March                                                        Singapore    Singapore   Retrospective case study     67            9               43.7 (14.1)       44.8%      ICU         \[[@pone.0238160.ref031]\]
  Young B        03-March                                                        Sengkang     Singapore   Descriptive case series      18            7               50.3 (31.1)       50%        NA          \[[@pone.0238160.ref062]\]
  Wu J           29-February                                                     Jiangsu      China       Retrospective case study     80            7               46.1 (15.4)       51.2%      NA          \[[@pone.0238160.ref056]\]
  Li K           29-February                                                     Chongqing    China       Retrospective case study     83            9               45.5 (12.3)       47%        Severity    \[[@pone.0238160.ref037]\]
  Liu W          28-February                                                     Wuhan        China       Retrospective case study     78            9               42.7 (17.8)       50%        NA          \[[@pone.0238160.ref039]\]
  Yang W         26-February                                                     Zhejiang     China       Retrospective case study     149           6               45.1 (13.3)       45.6%      NA          \[[@pone.0238160.ref060]\]
  Wu J           25-February                                                     Chongqing    China       Retrospective case study     80            6               44 (11)           48%        NA          \[[@pone.0238160.ref057]\]
  Shi H          24-February                                                     Wuhan        China       Retrospective case study     81            7               49.5 (11)         48%        NA          \[[@pone.0238160.ref047]\]
  Yang X         24-February                                                     Wuhan        China       Retrospective case study     52            9               59.7 (13.3)       33%        Mortality   \[[@pone.0238160.ref061]\]
  Zhang J        23-February                                                     Wuhan        China       Retrospective case study     138           9               56.3 (45.9)       49.3%      Severity    \[[@pone.0238160.ref064]\]
  Zhou W         21-February                                                     Wuhan        China       Retrospective case study     15            8               61.7 (9.6)        33.3%      Mortality   \[[@pone.0238160.ref068]\]
  Xu X           19-February                                                     Zhejiang     China       Retrospective case study     62            7               41.7 (14.8)       44%        NA          \[[@pone.0238160.ref059]\]
  Pan F          13-February                                                     Wuhan        China       Retrospective case study     21            6               40 (9)            74%        NA          \[[@pone.0238160.ref044]\]
  Chang D        07-February                                                     Beijing      China       Retrospective case study     13            6               38.7 (10.4)       23.1%      NA          \[[@pone.0238160.ref023]\]
  Wang D         07-February                                                     Wuhan        China       Retrospective case study     138           9               55.3 (19.2)       45.7%      ICU         \[[@pone.0238160.ref052]\]
  Huang C        24-January                                                      Wuhan        China       Prospective cohort study     41            9               49.3 (12.6)       27%        ICU         \[[@pone.0238160.ref001]\]

\*All articles were published in 2020.

NA: not applicable.

Pooled estimates of laboratory parameters: Single-arm meta-analysis {#sec018}
-------------------------------------------------------------------

The final pooled estimates of single-arm meta-analysis included 52 eligible articles. The pooled mean of laboratory parameters and 95%CI among SARS-CoV-2 infected patients, including hematological, immunological, and inflammatory variables, is illustrated in [Table 2](#pone.0238160.t002){ref-type="table"}. Our results depicted a wide variability between studies for each laboratory marker. Apart from immunoglobulins, IL-2R, and IL-8, significant heterogeneity was observed. Subgroup analysis by sample size and city of origin and sensitivity analysis failed to reveal the source of variation for each parameter. Additionally, meta-regression also rendered insignificant results.

10.1371/journal.pone.0238160.t002

###### Pooled estimates of single-arm meta-analysis for laboratory parameters in COVID-19 patients.
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  Laboratory testing         Number studies   Sample size   Estimate   95% CI          P-value   Q         P-value   I^2^    T^2^
  -------------------------- ---------------- ------------- ---------- --------------- --------- --------- --------- ------- ---------
  **CBC**                                                                                                                    
   White blood cells         47               5967          5.82       5.24, 6.40      \<0.001   7136.1    \<0.001   99.35   3.83
   Neutrophil count          31               3814          3.70       3.48, 3.92      \<0.001   525.8     \<0.001   93.9    0.31
   Lymphocyte count          45               6017          0.99       0.91, 1.08      \<0.001   7645.2    \<0.001   99.3    0.07
   Monocyte count            18               2586          0.42       0.39, 0.44      \<0.001   263.7     \<0.001   93.5    0.003
   Eosinophils count         4                546           0.02       0.01, 0.024     \<0.001   10.6      0.014     71.6    0.0
   Red blood cells           2                507           4.42       3.81, 4.67      \<0.001   50.8      \<0.001   98.03   0.095
   Hemoglobin                26               3114          129.1      125.0, 133.3    \<0.001   1504.3    \<0.001   98.3    103.4
   Platelet count            34               4347          178.4      171.9, 184.9    \<0.001   390.2     \<0.001   91.5    273.5
  **Coagulation profile**                                                                                                    
   Prothrombin time          22               3287          12.38      11.8, 12.9      \<0.001   3415.7    \<0.001   99.3    1.905
   APTT                      19               3023          31.8       30.2, 33.4      \<0.001   1312.1    \<0.001   98.6    11.96
   Thrombin time             2                754           21.9       8.29, 35.57     0.002     1908.1    \<0.001   99.94   96.86
   D-dimer                   27               3857          1.25       0.67, 1.82      \<0.001   40947.5   \<0.001   99.9    2.22
   Fibrinogen                2                781           2.45       0.61, 4.29      0.009     46.19     \<0.001   97.83   1.729
  **Inflammatory markers**                                                                                                   
   Ferritin                  8                528           889.5      773.2, 1005.7   \<0.001   16.61     0.020     57.8    14138.9
   ESR                       13               1013          37.85      29.07, 46.6     \<0.001   692.4     \<0.001   98.26   239.7
   Procalcitonin             25               3010          0.10       0.07, 0.12      \<0.001   3913.6    \<0.001   99.3    0.003
   C-reactive protein        36               4409          28.11      24.7, 31.4      \<0.001   3432.1    \<0.001   98.9    79.35
  **Immunoglobulins**                                                                                                        
   IgA                       2                101           2.21       2.15, 2.27      \<0.001   0.089     0.76      0.0     0.0
   IgG                       2                101           11.54      11.2, 11.8      \<0.001   1.88      0.17      46.9    0.023
   IgM                       2                101           1.00       0.96, 1.04      \<0.001   1.11      0.29      10.32   0.0
  **Complement test**                                                                                                        
   C3                        2                101           0.95       0.80, 1.10      \<0.001   28.02     \<0.001   96.43   0.011
   C4                        2                101           0.24       0.21, 0.27      \<0.001   28.08     \<0.001   96.44   0.0
  **Interleukins**                                                                                                           
   IL-2R                     2                101           762.3      732.4, 792.2    \<0.001   0.33      0.56      0.0     0.0
   IL-4                      2                276           2.98       1.09, 4.87      0.002     958.765   \<0.001   99.9    1.85
   IL-6                      12               926           11.56      9.82, 13.3      \<0.001   144.7     \<0.001   92.4    6.19
   IL-8                      2                101           18.4       17.08, 19.84    \<0.001   1.54      0.21      35.3    0.39
   IL-10                     3                292           6.33       4.39, 8.27      \<0.001   133.1     \<0.001   98.4    2.89
   TNF-α                     3                292           6.72       1.33, 12.12     0.015     2933.6    \<0.001   99.9    22.7
  **Immune cells**                                                                                                           
   CD4^+^ T cells            6                296           361.1      254.0, 468.2    \<0.001   88.7      \<0.001   94.3    15973.1
   CD8^+^ T cells            5                285           219.6      157.1, 282.0    \<0.001   46.17     \<0.001   91.3    4437.2
   T lymphocytes             2                167           704.3      254.5, 1154.0   0.002     27.6      \<0.001   96.3    101500

Test of association: standardized mean difference, Random model. 95% CI: 95% confidence interval, Q statistic: a measure of weighted squared deviations that denotes the ratio of the observed variation to the within-study error, I^2^: the ratio of true heterogeneity to total observed variation, T^2^: Tau squared, and it is referred to the extent of variation among the effects observed in different studies. Laboratory markers (INR and B lymphocytes) were reported in only one study thus were not shown. CBC: Complete blood picture, APTT: Activated partial thromboplastin time, ESR: Erythrocyte sedimentation rate. Ig: immunoglobulin, IL-2R: Interleukin-2 receptor, TNF- α: tumor necrosis factor-alpha.

Pooled estimates of laboratory parameters according to disease severity: Pairwise meta-analysis {#sec019}
-----------------------------------------------------------------------------------------------

Two-arms meta-analyses were then conducted for three pairwise comparisons; (1) Severe *versus* mild COVID, (2) ICU admitted patients *versus* the general ward, and (3) Expired *versus* survivors ([Table 3](#pone.0238160.t003){ref-type="table"}).

10.1371/journal.pone.0238160.t003

###### Pooled estimates of two-arms meta-analysis for laboratory parameters in COVID-19 patients.

![](pone.0238160.t003){#pone.0238160.t003g}

  Laboratory test      No of studies   Sample size   Effect size   Heterogeneity                                                        
  -------------------- --------------- ------------- ------------- ---------------------- ----------------------- --------- ----------- ---------
  **(A) Severity**                     **Mild**      **Severe**                                                                         
  White blood cells    **14**          1007          634           0.31 (0.11, 0.52)      **1.75 (1.21, 2.54)**   0.002     **62.9**    \<0.001
  Neutrophil count     **14**          959           599           0.53 (0.3, 0.76)       **2.62 (1.72, 3.97)**   \<0.001   **67.61**   \<0.001
  Lymphocyte count     **16**          680           1128          -0.66 (-0.9, -0.41)    **0.30 (0.19, 0.47)**   \<0.001   **77.36**   \<0.001
  Monocyte count       5               390           500           -0.08 (-0.23, 0.05)    0.86 (0.67, 1.12)       0.23      0.0         0.49
  Hemoglobin           4               70            200           -0.22 (-0.51, 0.06)    0.67 (0.40, 1.12)       0.12      0.0         0.91
  Platelet count       7               219           588           -0.32 (-0.47, -0.16)   **0.56 (0.42, 0.74)**   \<0.001   0.0         0.76
  Prothrombin time     6               215           521           0.33 (0.004, 0.67)     **1.82 (1.00, 3.33)**   0.047     **72.0**    0.003
  APTT                 5               146           386           -0.23 (-0.79, 0.33)    0.66 (0.24, 1.82)       0.42      85.5        \<0.001
  D-dimer              9               301           719           0.76 (0.53, 0.99)      **3.97 (2.62, 6.02)**   \<0.001   **55.65**   0.021
  Ferritin             2               297           176           1.003 (-0.08, 2.09)    6.17 (0.87, 43.9)       0.07      79.21       0.028
  Fibrinogen           3               45            144           0.63 (0.27, 0.99)      **3.14 (1.64, 6.00)**   \<0.001   0.0         0.81
  ESR                  2               302           277           0.26 (0.08, 0.44)      **1.60 (1.16, 2.22)**   0.004     0.0         0.43
  Procalcitonin        **10**          565           716           0.86 (0.5, 1.22)       **4.76 (2.48, 9.14)**   \<0.001   **86.1**    \<0.001
  C-reactive protein   **13**          605           928           1.02 (0.65, 1.4)       **6.36 (3.22, 12.5)**   \<0.001   88.2        \<0.001
  IgA                  2               355           301           0.13 (-0.03, 0.29)     1.27 (0.95, 1.69)       0.11      3.398       0.30
  IgG                  2               355           301           0.21 (-0.301, 0.72)    1.46 (0.58, 3.69)       0.41      88.3        0.003
  IgM                  2               355           301           -2.37 (-6.64, 1.89)    0.01 (0.00, 30.6)       0.27      99.56       \<0.001
  Complement 3         2               355           301           0.18 (-0.1, 0.47)      1.39 (0.83, 2.32)       0.20      64.70       0.09
  Complement 4         2               355           301           0.13 (-0.16, 0.43)     1.27 (0.74, 2.16)       0.38      66.83       0.08
  IL-4                 2               355           301           1.01 (-0.85, 2.87)     6.25 (0.2, 181.1)       0.28      97.17       \<0.001
  IL-6                 7               85            246           0.41 (0.014, 0.81)     **2.10 (1.02, 4.32)**   0.043     **84.38**   \<0.001
  IL-10                3               371           412           0.88 (0.43, 1.33)      **4.93 (2.18, 11.1)**   \<0.001   **82.81**   0.003
  TNF-α                3               371           412           0.6 (-0.17, 1.37)      2.97 (0.74, 11.9)       0.12      94.28       \<0.001
  CD4^+^ T cells       2               80            145           -1.87 (-2.39, -1.36)   **0.03 (0.01, 0.09)**   \<0.001   29.8        0.23
  CD8^+^ T cells       2               80            145           -1.8 (-2.12, -1.48)    **0.04 (0.02, 0.07)**   \<0.001   0.0         0.71
  **(B) Admission**                    **Floor**     **ICU**                                                                            
  White blood cells    3               64            149           0.85 (0.54, 1.15)      **4.67 (2.70, 8.10)**   \<0.001   0.0         0.56
  Neutrophil count     4               73            207           1.86 (0.59, 3.14)      **29.1 (2.9, 291.8)**   0.004     **93.14**   \<0.001
  Lymphocyte count     4               73            207           -0.81 (-1.36, -0.27)   **0.23 (0.09, 0.62)**   0.003     **68.59**   0.023
  Monocyte count       3               60            179           -0.308 (-1.15, 0.53)   0.57 (0.13, 2.59)       0.47      83.77       0.002
  Hemoglobin           2               22            86            -1.1 (-1.97, -0.24)    **0.14 (0.03, 0.64)**   0.012     **66.31**   0.08
  Platelet count       4               73            207           -0.06 (-0.33, 0.2)     0.90 (0.56, 1.45)       0.64      0.0         0.54
  Prothrombin time     3               64            149           0.43 (0.09, 0.76)      **2.18 (1.19, 3.99)**   0.012     14.28       0.31
  APTT                 3               64            149           -0.22 (-0.51, 0.07)    0.67 (0.40, 1.13)       0.14      0.0         0.78
  D-dimer              3               64            149           0.79 (0.35, 1.24)      **4.19 (1.88, 9.35)**   \<0.001   44.94       0.16
  **(C) Mortality**                    **Alive**     **Died**                                                                           
  White blood cells    6               736           392           0.91 (0.61, 1.22)      **5.21 (3.00, 9.05)**   \<0.001   **78.05**   \<0.001
  Neutrophil count     3               475           222           1.01 (0.4, 1.63)       **6.25 (2.05, 19.0)**   0.001     **90.9**    \<0.001
  Lymphocyte count     7               756           424           -0.85 (-1.28, -0.41)   **0.21 (0.10, 0.47)**   \<0.001   **89.33**   \<0.001
  Monocyte count       4               483           229           -0.18 (-0.47, 0.1)     0.72 (0.43, 1.21)       0.21      57.48       0.070
  Hemoglobin           5               600           271           0 (-0.15, 0.15)        1.00 (0.76, 1.31)       0.99      4.988       0.378
  Platelet count       6               640           315           -0.46 (-0.71, -0.21)   **0.43 (0.28, 0.68)**   \<0.001   **59.52**   0.030
  Prothrombin time     6               640           315           0.64 (0.25, 1.03)      **3.19 (1.58, 6.47)**   0.001     83.0        \<0.001
  APTT                 4               483           229           -0.096 (-0.51, 0.31)   0.83 (0.40, 1.75)       0.646     78.23       0.003
  D-dimer              5               620           283           1.02 (0.85, 1.18)      **6.36 (4.72, 8.58)**   \<0.001   10.63       0.34
  Ferritin             3               338           211           0.94 (0.26, 1.62)      **5.50 (1.6, 18.83)**   0.006     **91.63**   \<0.001
  ESR                  2               201           157           0.33 (0.08, 0.58)      **1.82 (1.16, 2.86)**   0.008     20.03       0.263
  Procalcitonin        3               580           239           0.96 (0.43, 1.49)      **5.70 (2.18, 14.9)**   \<0.001   **81.48**   0.005
  C-reactive protein   4               591           331           1.08 (0.65, 1.52)      **7.09 (3.23, 15.5)**   \<0.001   **87.31**   \<0.001
  IL-6                 4               612           276           1.45 (1.11, 1.78)      **13.87 (7.6, 25.4)**   \<0.001   **75.44**   0.007
  CD4^+^ T cells       2               314           109           -0.67 (-1.01, -0.33)   **0.30 (0.16, 0.55)**   \<0.001   44.57       0.17
  CD8^+^ T cells       2               314           109           -0.832 (-1.1, -0.59)   **0.22 (0.15, 0.34)**   \<0.001   0.0         0.423

Continuous Random-Effects model, SMD: Standardized mean difference, OR 95% CI: Odds ratio 95% confidence interval, I^2^: the ratio of true heterogeneity to total observed variation. APTT: Activated partial thromboplastin time, ESR: Erythrocyte sedimentation rate. Ig: immunoglobulin, IL: Interleukin, TNF-α: tumor necrosis factor-alpha.

Laboratory parameters of 16 eligible records were utilized to compare between severe and non-severe patients. Severe cohorts were more likely to have high blood levels of white blood cells (OR = 1.75, 95%CI = 1.21--2.54, *p* = 0.002), neutrophil count (OR = 2.62, 95%CI = 1.72--3.97, *p* \<0.001), prothrombin time (OR = 1.82, 95%CI = 1.00--3.33, *p* = 0.047), D-dimer (OR = 3.97, 95%CI = 2.62--6.02, *p* \<0.001), fibrinogen (OR = 3.14, 95%CI = 1.64--6.00, *p* \<0.001), erythrocyte sedimentation rate (OR = 1.60, 95%CI = 1.16--2.22, *p* \<0.001), procalcitonin (OR = 4.76, 95%CI = 2.48--9.14, *p* \<0.001), IL-6 (OR = 2.10, 95%CI = 1.02--4.32, *p* = 0.043), and IL-10 (OR = 4.93, 95%CI = 2.18--11.1, *p* \<0.001). In contrast, patients with normal lymphocyte count (OR = 0.30, 95%CI = 0.19--0.47, *p* \<0.001), platelet count (OR = 0.56, 95%CI = 0.42--0.74, *p* \<0.001), CD4^+^ T cells (OR = 0.04, 95%CI = 0.02--0.07, *p* \<0.001), and CD8^+^ T cells (OR = 0.03, 95%CI = 0.01--0.09, *p* \<0.001) were less likely to develop severe form of COVID-19 disease ([Table 3A](#pone.0238160.t003){ref-type="table"}).

Significant heterogeneity was observed in eight of these parameters, namely WBC (I^2^ = 62.9%, *p* \<0.001), neutrophil count (I^2^ = 67.6%, *p* \<0.001), lymphocyte count (I^2^ = 77.4%, *p* \<0.001), prothrombin time (I^2^ = 72%, *p* = 0.003), D-dimers (I^2^ = 55.6%, *p* = 0.021), procalcitonin (I^2^ = 86.1%, *p* \<0.001), IL-6 (I^2^ = 84.4%, *p* \<0.001), and IL-10 (I^2^ = 82.8%, *p* = 0.003).

Pooled estimates of laboratory parameters according to ICU admission: Pairwise meta-analysis {#sec020}
--------------------------------------------------------------------------------------------

A total of 4 eligible articles were recognized to include laboratory features of ICU and floor patients. Our data revealed having elevated levels of WBCs (OR = 5.21, 95%CI = 3.0--9.05, *p* \<0.001), neutrophils (OR = 6.25, 95%CI = 2.05--19.0, *p* = 0.001), D-dimer (OR = 4.19, 95%CI = 1.88--9.35, *p* \<0.001), and prolonged prothrombin time (OR = 2.18, 95%CI = 1.19--3.99, *p* = 0.012) were associated with increased odds of ICU admission, while normal lymphocyte count (OR = 0.23, 95%CI = 0.09--0.62, *p* = 0.003) and hemoglobin (OR = 0.14, 95%CI = 0.03--0.64, *p* = 0.012) conferred lower risk of ICU admission ([Table 3B](#pone.0238160.t003){ref-type="table"}).

Remarkable heterogeneity was obvious in studies of neutrophil count (I^2^ = 93.1%, *p* \<0.001), lymphocyte count (I^2^ = 68.5%, *p* = 0.023), and hemoglobin (I^2^ = 66.3%, *p* = 0.08). These parameters were enclosed in two to four studies; therefore, further tracing for the source of heterogeneity was not applicable.

Pooled estimates of laboratory parameters according to mortality: Pairwise meta-analysis {#sec021}
----------------------------------------------------------------------------------------

Of the included articles, 7 studies contained separate results for laboratory testing in survival *versus* expired patients. As depicted in [Table 3C](#pone.0238160.t003){ref-type="table"}, our data revealed increased odds of having elevated levels of WBC (OR = 5.21, 95%CI = 3.0--9.05, *p* \<0.001), neutrophils (OR = 6.25, 95%CI = 2.05--19.0, *p* = 0.001), prothrombin time (OR = 3.19, 95%CI = 1.58--6.47, *p* = 0.001), D-dimer (OR = 6.36, 95%CI = 4.72--8.58, *p* \<0.001), ferritin (OR = 5.50, 95%CI = 1.6--18.8, *p* = 0.006), ESR (OR = 1.82, 95%CI = 1.16--2.86, *p* = 0.008), procalcitonin (OR = 5.70, 95%CI = 2.18--14.9, *p* \<0.001), CRP (OR = 7.09, 95%CI = 3.23--15.5, *p* \<0.001), and IL-6 (OR = 13.87, 95%CI = 7.6--25.4, *p* \<0.001) in expired cases. However, patients with normal lymphocyte count (0.21 (0.10, 0.47, p \<0.001), platelet count (0.43 (0.28, 0.68, p \<0.001), CD4^+^ T cells (OR = 0.30 (0.16, 0.55, p \<0.001), and CD8^+^ T cells (OR = 0.22 (0.15, 0.34, p \<0.001) had higher chance of survival ([Table 3C](#pone.0238160.t003){ref-type="table"}).

Considerable heterogeneity was also noted in some of these parameters, namely WBC (I^2^ = 78.0%, *p* \<0.001), neutrophilic count (I^2^ = 90.9%, *p* \<0.001), lymphocyte count (I^2^ = 89.3%, *p* \<0.001), platelet count (I^2^ = 59.5%, *p* = 0.030), ferritin (I^2^ = 91.6%, *p* \<0.001), procalcitonin (I^2^ = 81.5%, *p* = 0.005), CRP (I^2^ = 87.3%, *p* \<0.001), and IL-6 (I^2^ = 75.4%, *p* = 0.007). Given the small number of enrolled studies with discriminated data on patients who survived or died, we failed to identify the source of heterogeneity.

Subgroup and sensitivity analysis {#sec022}
---------------------------------

For the studies which included a comparison between mild and severe patients, subgroup and sensitivity analyses were performed for five laboratory markers (WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP). First, to identify how each study affects the overall estimate of the rest of the studies, we performed leave-one-out sensitivity analyses. Results did not contribute to give explanations to heterogeneity. In contrast, subgroup analysis revealed homogeneity with certain categorizations. For WBCs lab results, heterogeneity was resolved on stratification by the origin of study population \[Wuhan population: I^2^ = 73.4%, *p* = 0.002, other cities: I^2^ = 0%, *p* = 0.53\] and month of publication \[April: I^2^ = 74.5%, *p* = 0.001, February/March: I^2^ = 47.5%, *p* = 0.06\]. Regarding neutrophilic count, the variance in the results resolved in articles with large sample size \>50 patients (I^2^ = 46.2%, *p* = 0.06). Moreover, the degree of dissimilarities of procalcitonin results found in different studies was ameliorated in April publications (I^2^ = 41.5%, *p* = 0.16) and in those with low sample size (I^2^ = 0%, *p* = 0.80). Similarly, homogeneity was generated in CRP results in articles with low sample size (I^2^ = 0%, *p* = 0.58) ([Table 4](#pone.0238160.t004){ref-type="table"}).

10.1371/journal.pone.0238160.t004

###### Tracing the source of heterogeneity of laboratory markers in studies comparing mild and severe COVID-19 patients.
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  Lab test                 Feature   Categories   Count of studies   Pooled estimates   Heterogeneity   Meta-regression                                                        
  ------------------------ --------- ------------ ------------------ ------------------ --------------- ----------------- --------- --------- ------------- ------- ------- -- --
  **White blood cells**    Overall                14                 0.317              0.113           0.52              0.002     62.90%    0.001                            
  Origin of patients       Others    8            0.113              -0.083             0.308           0.26              0%        0.53      *Reference*                      
  Wuhan                    6         0.490        0.198              0.783              0.00            73.40%            0.002     0.31      0.03          0.58    0.029      
  Sample size              ≤50       5            0.164              -0.553             0.881           0.65              71.30%    0.007     *Reference*                      
  \>50                     9         0.387        0.208              0.566              \<0.001         52.60%            0.031     0.30      -0.10         0.72    0.14       
  Publication month        Feb/Mar   8            0.251              0.039              0.464           0.021             47.50%    0.06      *Reference*                      
  April                    6         0.445        0.005              0.884              0.047           74.50%            0.001     0.11      -0.16         0.38    0.43       
  **Neutrophils**          Overall                14                 0.534              0.306           0.762             \<0.001   67.62%    \<0.001                          
  Origin of patients       Others    8            0.439              0.139              0.740           0.004             50.88%    0.047     *Reference*                      
  Wuhan                    6         0.632        0.280              0.985              \<0.001         78.29%            \<0.001   0.045     -0.21         0.30    0.20       
  Sample size              ≤50       5            0.286              -0.503             1.076           0.47              75.94%    0.002     *Reference*                      
  \>50                     9         0.65         0.472              0.828              \<0.001         46.2%             0.06      0.606     0.20          1.01    0.003      
  Publication month        Feb/Mar   8            0.428              0.181              0.675           \<0.001           54.4%     0.032     *Reference*                      
  April                    6         0.709        0.273              1.44               0.001           73.19%            0.002     0.312     0.06          0.55    0.014      
  **Lymphocytes**          Overall                16                 -0.663             -0.909          -0.417            \<0.001   77.36%    \<0.001                          
  Origin of patients       Others    9            -0.626             -0.962             -0.291          \<0.001           66.51%    0.002     *Reference*                      
  Wuhan                    7         -0.710       1.097              -0.323             \<0.001         85.72%            \<0.001   0.092     -0.31         0.49    0.64       
  Sample size              ≤50       5            -0.506             -1.169             0.156           0.13              66.1%     0.019     *Reference*                      
  \>50                     11        -0.714       -0.983             -0.444             \<0.001         80.98%            \<0.001   -0.342    -0.85         0.169   0.18       
  Publication month        Feb/Mar   9            -0.452             -0.712             -0.192          \<0.001           66.65%    0.002     *Reference*                      
  April                    7         -0.979       -1.354             -0.604             \<0.001         70.53%            0.002     -0.572    -0.97         -0.17   0.006      
  **Procalcitonin**        Overall                10                 0.868              0.508           1.228             \<0.001   88.16%    \<0.001                          
  Origin of patients       Others    5            1.038              0.370              1.706           \<0.001           86.16%    \<0.001   *Reference*                      
  Wuhan                    5         0.686        0.331              1.041              \<0.001         75.38%            0.003     -0.318    -0.97         0.33    0.34       
  Sample size              ≤50       3            0.768              0.334              1.203           \<0.001           0%        0.80      *Reference*                      
  \>50                     7         0.903        0.459              1.348              \<0.001         88.62%            \<0.001   0.054     -0.72         0.83    0.89       
  Publication month        Feb/Mar   6            0.956              0.404              1.509           \<0.001           91.51%    \<0.001   *Reference*                      
  April                    4         0.757        0.409              1.105              \<0.001         41.54%            0.16      -0.096    -0.80         0.61    0.78       
  **C-reactive protein**   Overall                13                 1.027              0.65            1.40              \<0.001   88.2%     \<0.001                          
  Origin of patients       Others    8            1.24               0.65               1.83            \<0.001           87.8%     \<0.001   *Reference*                      
  Wuhan                    5         0.389        0.30               1.07               \<0.001         80.7%             \<0.001   -0.58     -1.27         0.10    0.09       
  Sample size              ≤50       3            0.831              0.341              1.322           \<0.001           0%        0.58      *Reference*                      
  \>50                     10        1.08         0.651              1.512              \<0.001         82.3%             \<0.001   0.37      -0.55         1.29    0.42       
  Publication month        Feb/Mar   8            1.014              0.502              1.525           \<0.001           88.23%    \<0.001   *Reference*                      
  April                    5         1.07         0.548              1.600              \<0.001         75.1%             0.003     0.13      -0.59         0.86    0.71       

SMD: Standardized mean difference, LL: lower limit, UL: upper limit, I^2^: the ratio of true heterogeneity to total observed variation. Significant values indicate significance at *P* \< 0.05.

Meta-regression analysis {#sec023}
------------------------

Considering the number of the included studies with severity, ICU admission, and mortality data was rather small, we performed meta-regression analyses for only five parameters (mentioned above) in studies comparing mild and severe disease ([Table 4](#pone.0238160.t004){ref-type="table"}).

For WBCs, higher difference between mild and severe cohorts was noted in Wuhan studies than other population (coefficient = 0.31, 95%CI = 0.03, 0.58, *p* = 0.029). Moreover, articles with larger sample size exhibited a wider variation of neutrophilic count between severe and non-severe cases (coefficient = 0.60, 95%CI = 0.20, 1.01, *p* = 0.003). For the same marker, later studies published in April also showed higher difference compared to those published in February and March (coefficient = 0.31, 95%CI = 0.06, 0.55, *p* = 0.014). In contrast, more reduction of lymphocytes was observed in April articles than earlier ones (coefficient = -0.57, 95%CI = -0.97, -0.17, *p* = 0.006).

Publication bias {#sec024}
----------------

Publication bias was performed to the same five parameters with study count ≥10 ([S1 Fig](#pone.0238160.s003){ref-type="supplementary-material"}). Visual inspection of the funnel plots suggested symmetrical distribution for all laboratory parameters tested. The Egger test (*p* \> 0.1) confirmed that there was no substantial evidence of publication bias; Egger's regression *p* values were 0.44, 0.50, 0.68, 0.56, and 0.22 for WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP, respectively.

Decision tree and Receiver Operating Characteristic (ROC) curve {#sec025}
---------------------------------------------------------------

To identify predictors for severity, decision tree analysis was applied using multiple laboratory results. High performance of classification was found with the usage of a single parameter; neutrophilic count identified severe patients with 100% sensitivity and 81% specificity at a cut-off value of \>3.74 identified by the specified decision tree model. Further analysis of the area under the curve of input data is shown in [Table 5](#pone.0238160.t005){ref-type="table"}.

10.1371/journal.pone.0238160.t005

###### Receiver operating characteristics results for severity of COVID-19.
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  Lab test        AUC            Threshold   Sensitivity   Specificity   P-value
  --------------- -------------- ----------- ------------- ------------- -------------
  WBC             0.801 ± 0.09   5.47        85.7          85.7          **0.007**
  Neutrophil      0.831 ± 0.09   3.74        78.5          100           **0.003**
  Lymphocyte      0.867 ± 0.06   0.98        81.2          87.5          **\<0.001**
  Platelets       0.836 ± 0.11   177.6       71.4          71.4          **0.035**
  PT              0.583 ± 0.17   12.9        50.0          83.3          0.63
  Procalcitonin   0.845 ± 0.09   0.06        80.0          90.0          **0.007**
  D-dimer         0.876 ± 0.08   0.48        88.9          77.8          **0.007**
  CRP             0.875 ± 0.08   38.2        84.6          92.3          **0.001**
  IL-6            0.632 ± 1.6    22.9        71.4          71.4          0.40

AUC: area under the curve, WBC: white blood cells, PT: prothrombin time, CRP: C-reactive protein, IL-6: interleukin 6. Bold values indicate significance at *P* \< 0.05.

Trial sequential analysis {#sec026}
-------------------------

As elaborated by the decision tree algorithm for the role of neutrophilic count on decision-making to discriminate between COVID-19 patients with a mild and severe presentation, TSA was employed on that particular laboratory parameter to test for the presence of sufficient studies from which results were drawn. The sample size of studies containing neutrophilic count information and classifying cohorts into mild and severe COVID-19 infection accounted for a total of 1,558 subjects. TSA illustrated crossing of the monitoring boundary by the cumulative Z-curve before reaching the required sample size, suggesting that the cumulative proof was acceptable, and no additional future studies are needed to authenticate the significances ([Fig 2](#pone.0238160.g002){ref-type="fig"}).

![Trial sequential analysis.\
Trial sequential analysis (TSA) for the neutrophil count. The acquired sample size of the neutrophil count was 1558 subjects and the cumulative Z-curve crossed the monitoring boundary before reaching the required sample size (n = 540), suggesting that the cumulative proof was reliable, and no additional trials are required to achieve the significance.](pone.0238160.g002){#pone.0238160.g002}

Discussion {#sec027}
==========

During the last few months, the prevalence of COVID-19 infection was increased daily among different countries overall in the world. Thus, the need to assess the disease severity and mortality are required to limit the pervasiveness of this pandemic \[[@pone.0238160.ref071]\]. A diverse of abnormal laboratory parameters including hematological, inflammatory as well as immunological markers thought to be raised throughout COVID-19 outbreak \[[@pone.0238160.ref002], [@pone.0238160.ref072]\]. In this comprehensive meta-analysis, our team attempted to interpret the distinct questions raised about the various spectrum of laboratory parameters associated with the severity and mortality of COVID-19. At the beginning of this workflow, our team investigated different hematological, inflammatory, and immunological variables of 6320 patients diagnosed with COVID-19. Our findings using random-effect models revealed increased levels of WBCs and neutrophil counts that were significantly associated with higher odds ratio among severe, ICU admission and Expired patients with COVID-19. On the contrary, the levels of lymphocyte and platelet counts were lowered among severe and expired patients with COVID-19. Also, we observed depletion in quantities of CD4^+^ T cells and CD8^+^ T cells among severe and mortality patients.

Nevertheless, in patients with the COVID-19 outbreak, the WBC count can vary \[[@pone.0238160.ref073]\]. Other reports indicated that leukopenia, leukocytosis, and lymphopenia have been reported, although lymphopenia appears most common \[[@pone.0238160.ref074], [@pone.0238160.ref075]\]. Another study supported that lymphopenia is an effective and reliable indicator of the severity and hospitalization in COVID-19 patients \[[@pone.0238160.ref076]\]. The additional report suggested that COVID-19 illness might be implicated with CD4^+^ and CD8^+^ T cells depletion through acting on lymphocytes, especially T lymphocytes \[[@pone.0238160.ref034]\]. A recent meta-analysis study discovered that the severity among COVID-19 patients might correlate with higher levels of WBCs count and lower levels of lymphocyte, CD4^+^ T cells, and CD8^+^ T cells counts \[[@pone.0238160.ref072]\]. In this respect, we could speculate that the depletion in the number of lymphocytes count is directly proportional with the severity of COVID-19 infection and the high survival rate of the disease is associated with the ability to renovate lymphocyte cells, particularly T lymphocytes which are crucial for destroying the infected viral particles \[[@pone.0238160.ref077]\]. During disease severity, remarkable thrombocytopenia was observed and confirmed by Lippi and his colleagues that revealed a reduction of platelet count among severe and died patients with COVID-19 supporting that thrombocytopenia could consider as an exacerbating indicator during the progression of the disease \[[@pone.0238160.ref078]\]. Therefore, our findings could support Shi et al. conclusion that high WBC count with lymphopenia could be considered as a differential diagnostic criterion for COVID-19 \[[@pone.0238160.ref079]\].

Considering coagulation profile, our team observed a prolonged in most coagulation markers among severe, ICU and expired patients, especially prothrombin time, fibrinogen, D-dimer, but with normal proportions of activated partial thromboplastin time (APTT) that could focus the light on the pathogenesis of COVID-19 infection through interfering with extrinsic coagulation pathway. A recently published report concluded similar findings in the form of observation of higher levels prothrombin time, D-dimer along fibrin degradation products among non-survival compared with survival patients \[[@pone.0238160.ref080]\].

Numerous studies illustrated the pathogenesis action of COVID-19 with the induction of cytokine storm throughout the progressive phase of the infection \[[@pone.0238160.ref072], [@pone.0238160.ref081], [@pone.0238160.ref082]\]. The generation of cytokine storm within COVID-19 patients required increased levels of IFN-γ and IL-1β that could stimulate the cellular response of T helper type 1 (Th1) which has a crucial function in the acceleration of specific immunity against COVID-19 outbreak \[[@pone.0238160.ref081]\]. Due to the elevated levels of IL-2R and IL-6 accompanied by the advancement of COVID-19, several cytokines secreted by T helper type 2 (Th2) cells that could neutralize the inflammatory responses including IL-4 and IL-10 \[[@pone.0238160.ref072], [@pone.0238160.ref081]\]. Our findings revealed a significantly associated with elevated levels of anti-inflammatory cytokines involving IL-6 and IL-10 among severe and expired patients with COVID-19. A recent study indicated a similar assumption with these findings and identified elevated levels of IL-6 and IL-10 among non-survived compared with survived patients \[[@pone.0238160.ref009]\]. Another confirmation of this conclusion is confirmed by a newly published meta-analysis report that indicated an exaggerated elevation of IL-6 and IL-10 throughout the severe level of COVID-19 infection \[[@pone.0238160.ref072]\].

Concerning the inflammatory markers associated with the COVID-19 pandemic, this comprehensive meta-analysis study observed higher concentrations of C-reactive protein (CRP) and procalcitonin besides elevated erythrocyte sedimentation rate (ESR) levels among severe and expired patients with COVID-19. Recently, Henry et al. established a meta-analysis survey and corroborated this finding with a higher significance of CRP and procalcitonin levels \[[@pone.0238160.ref072]\]. Other recent reports identified higher levels of CRP among severe patients with COVID-19 infection \[[@pone.0238160.ref076]\]. An additional meta-analysis survey established based on four recent articles indicated prolonged levels of procalcitonin among severe patients with COVID-19 \[[@pone.0238160.ref083]\]. In this respect, we might speculate the potential role of procalcitonin as a prognostic biomarker during the severe status of COVID-19. Finally, our team revealed increased levels of serum ferritin among non-survived patients compared with survived patients, and this significant outcome was observed in another meta-analysis study among severe and non-survival patients with COVID-19 infection \[[@pone.0238160.ref072]\].

This comprehensive meta-analysis confronted several limitations that raised throughout the processing of the outcomes. First, the insufficient laboratory data concerning the interest of design causing the increasing bias among different covariates. Second, the variation in the characteristics among different articles concerning the severity and survival of COVID-19. Third, the small sample sizes of some studies besides most of the concerned articles were established within China, especially Wuhan. Finally, there was an observed publication bias and heterogeneity in this comprehensive meta-analysis.

Conclusion {#sec028}
==========

In conclusion, several laboratory parameters could associate with the severity and mortality of COVID-19 infection and should be screened and measured continuously during the progression of this pandemic. These parameters included WBCs count, lymphocytes, platelet count, prothrombin time, D-dimer, and fibrinogen. Also, various interleukins could serve as anti-inflammatory markers such as IL-6, and IL-10 and should be evaluated. The estimation of other inflammatory biomarkers like CRP and procalcitonin could be helpful in the monitor the severity of the disease.
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======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.
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###### Publication bias.

Funnel plot of standard error by the standardized difference in means for (A) White blood cells, (B) Neutrophil count, (C) Lymphocyte count, (D) Procalcitonin, and (E) C-reactive protein. The standard error provides a measure of the precision of the effect size as an estimate of the population parameter. It starts with zero at the top. Studies with smaller sample sizes produce less precise estimated effects with a broader base. The pooled estimated effects would be expected to scatter symmetrically around the total overall estimate of the meta-analysis (represented by the vertical line). Each circle represents a study (black circle). In the case of asymmetry, Duval and Tweedie's trim and fill method predict the missing studies (red circle). Begg's and Egger's tests were performed. *P* values \<0.1 were set to have a significant bias.

(TIF)
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Click here for additional data file.
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The map in Fig 1 B is curated by the authors using Tableau 2020.1 Desktop Professional Edition (<https://www.tableau.com/>). These data were provisded in the figure legend to clarify this issue and cite the vendor in the text.

Reviewer \#1

The review is written well. But it needs several refinements.

Author Response:

Dear Prof. Sarman Singh

We appreciate the time put in reviewing this manuscript. Thank you for the constructive comments. The authors followed it.

1\. The abstract (results): The values of parameters must be given with indicative conclusions. The reader will read the abstract before deciding to read the full article or not. Unfortunately, the abstract is not well written.
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Thank you for the remark. The abstract has been revised to be attractive for future readers.

2\. Too many tables and same data is presented in the figures 2 and 3. I strongly feel that that Figure 2 and 3 are not represented correctly. Each panel of these figures deserve a separate independent figure. The journal also advises how to format a figure/graphs. The authors should use that format. The current form of these two important figures (having so many panels within) are not readable and have been made irrelevant.
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Thank you for the remark. The conclusion has been revised and highlighted according to the valued suggestion.
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1\. Line 154:  Next, in the presence of individual patient data, single-armed observed values were converted to two-armed data to act as each other's control group based on covariate information.

Please provide Reference for articles presented with individual data.

2\. Line 162: For severity pairwise comparison, estimates of SMD served as quantitative measures of the strength of evidence against the null hypothesis of no difference in the population between mild and severe COVID-19 manifestations.

Line 165: SMD of \<0.2, 0.2-0.8, and \>0.8 indicated mild, moderate, and severe strength.

Line 166:  For ICU admission, survival analysis, overall effect size estimates in SMD were then converted to the odds ratio (OR) with 95%CI for better interpretation by clinical domains.

What about moderate group defined by SMD 0.2-0.8?

3\. Line: 168: Decision tree to identify predictors for poor outcomes

In the manuscript, only severity was analyzed.

4\. Line169:  Using laboratory features for clinical prediction, the decision tree algorithm was employed to identify the key risk factors attributed to severe COVID-19 infection.

For Risk factor? Not for cutoff value? No matter whatever it is, please provide the decision tree results as supplemental material.

5\. Line 216: Ultimately, a total of 52 eligible articles were included for the quantitative synthesis of this meta-analysis study, with 52 records represented single-arm analysis, 16 records represented two-arms

Sixteen included articles have both single- and two-arms design?
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6\. Line 236:  descriptive case series, and one case-control study.
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What is difference between case series and case records here?

7.Table 1

1)Journal name and Publication date are not necessary to be included.
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8\. table 2
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9.Table 5

Specify the outcome "severity of COVID19"in the title.

10.Figure 2.
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11.Subgroup analyses
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12.Time point of collection of lab parameters and clinic symptoms?
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